Nexentis Technologies Inc. (NXTS): Nasdaq/NYSE listing notice — N2OFF receives Nasdaq bid price deficiency notice; 180-day cure period

Nexentis Technologies Inc.

On March 28, 2025, Nasdaq notified N2OFF that its stock closed below $1.00 for 30 consecutive business days.
Company has until September 24, 2025 to regain compliance with Nasdaq Listing Rule 5550(a)(2).
If not compliant, may seek a second 180-day period by meeting other listing standards and planning a reverse stock split.
Common stock continues trading on Nasdaq under symbol NITO during the compliance period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Nexentis Technologies Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)

Exact text from the filing

March 28, 2025, N2OFF, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid price required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Notice”). This Notice has no immediate effect on the listing of the Company’s Common Stock which will con

View on SEC.gov

Browse all listing & compliance notices →

Nexentis Technologies Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-001431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.